Dimensional Fund Advisors LP trimmed its stake in shares of NewLink Genetics Corp (NASDAQ:NLNK) by 35.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,093 shares of the biotechnology company’s stock after selling 42,674 shares during the quarter. Dimensional Fund Advisors LP’s holdings in NewLink Genetics were worth $795,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. grew its holdings in NewLink Genetics by 337.3% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 328,000 shares of the biotechnology company’s stock worth $3,339,000 after acquiring an additional 253,000 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in NewLink Genetics by 207.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 311,927 shares of the biotechnology company’s stock worth $3,176,000 after acquiring an additional 210,360 shares during the last quarter. American Century Companies Inc. bought a new stake in NewLink Genetics during the 3rd quarter worth approximately $963,000. Tudor Investment Corp ET AL bought a new stake in NewLink Genetics during the 2nd quarter worth approximately $286,000. Finally, Alliancebernstein L.P. grew its holdings in NewLink Genetics by 88.6% during the 2nd quarter. Alliancebernstein L.P. now owns 61,300 shares of the biotechnology company’s stock worth $451,000 after acquiring an additional 28,800 shares during the last quarter. Institutional investors and hedge funds own 52.68% of the company’s stock.

Shares of NewLink Genetics Corp (NLNK) opened at $6.81 on Friday. NewLink Genetics Corp has a 12 month low of $5.90 and a 12 month high of $25.17. The company has a market cap of $221.91, a price-to-earnings ratio of -2.79 and a beta of 1.15.

A number of research firms have weighed in on NLNK. BidaskClub raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Jefferies Group reduced their target price on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Stifel Nicolaus boosted their target price on shares of NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 target price on shares of NewLink Genetics in a report on Thursday, November 2nd. Finally, Zacks Investment Research lowered shares of NewLink Genetics from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. NewLink Genetics has an average rating of “Buy” and a consensus target price of $23.29.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://theolympiareport.com/2018/02/11/newlink-genetics-corp-nlnk-shares-sold-by-dimensional-fund-advisors-lp.html.

NewLink Genetics Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.